Palliative nephrectomy until targeted therapy of disseminated kidney cancer patients
| Autor: | A. V. Klimov, M. I. Volkova, V. I. Shirokograd, S. A. Kalinin, M. V. Peters, V. B. Matveev |
|---|---|
| Jazyk: | ruština |
| Rok vydání: | 2015 |
| Předmět: |
medicine.medical_specialty
Urology medicine.medical_treatment overall survival Gastroenterology Targeted therapy Renal cell carcinoma Internal medicine medicine postoperative complications Radiology Nuclear Medicine and imaging Progression-free survival Adverse effect Kidney business.industry prognostic factors toxicity Odds ratio disseminated kidney cancer medicine.disease targeted therapy somatic status Nephrectomy adverse events Surgery palliative nephrectomy medicine.anatomical_structure Oncology Nephrology Medicine business Kidney cancer progression-free survival |
| Zdroj: | Onkourologiâ, Vol 11, Iss 3, Pp 24-33 (2015) |
| ISSN: | 1996-1812 1726-9776 |
| Popis: | Objective: to assess the role of palliative nephrectomy in disseminated kidney cancer patients planned to undergo targeted antiangiogenic treatment. Subjects and methods . The investigation included data on 83 patients with T1-4N0 / +M1 disseminated renal cell carcinoma (RCC) who had received at least 2 targeted therapy cycles in 2009 to 2011. In 48 (57.8 %) patients, the treatment was preceded by palliative nephrectomy that was not carried out in 35 (42.2 %). Before starting targeted therapy, all the cases were confirmed to be diagnosed with clear cell RCC, with a sarcomatoid component being in 7 (8.4 %) patients. The median follow-up of all the patients was 21 (12–36) months. Results. The unremoved affected kidney in disseminated kidney cancer patients receiving targeted antiangiogenic therapy is an independent factor for the poor prognosis of progression-free (odds ratio (OR), 2.4; 95 % confidence interval (CI), 1.2–4.7) and overall (OR, 2.8; 95 % CI, 1.3–6.3) survival. Palliative nephrectomy does not improve the prognosis in patients with a low somatic status, the N+ category, and metastases into the bones and nonregional lymph nodes. Conclusion. Palliative nephrectomy in the selected patients with disseminated kidney cancer on targeted antiangiogenic therapy increases progression-free and overall survival. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|